Breast CancerPhase 3NCT00016406
S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer
A Phase 3 study testing filgrastim, cyclophosphamide and doxorubicin in people with Breast Cancer, run by SWOG Cancer Research Network at 314 sites in United States.
Trial summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combination chemotherapy is more effective with or without filgrastim in treating breast cancer. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- filgrastim, cyclophosphamide and doxorubicin
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 399 participants
- Where
- 314 sitesUnited States
- Study dates
- May 2001to Feb 2012
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed inflammatory or locally advanced breast cancer
- Stage IIB (T3, N0, M0), IIIA (T3, N1-2, M0 or T0-2, N2, M0), or IIIB (T4, any N, M0 or any T, N3, M0)
- Unresectable or otherwise appropriate for neoadjuvant therapy
- Confirmed by core needle or incisional biopsy
- Punch biopsy allowed if invasive disease is documented
- No distant metastases
- Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age:
- Not specified
Sex:
- Female
Menopausal status:
- Not specified
Performance status:
- Zubrod 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than upper limit of normal (ULN)
- SGOT or SGPT no greater than 2 times ULN
Renal:
- Creatinine no greater than ULN
Cardiovascular:
- No congestive heart failure or angina pectoris
- LVEF greater than lower limit of normal
Other:
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- HIV negative
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy for breast cancer
Endocrine therapy:
- No prior hormonal therapy for breast cancer
Radiotherapy:
- No prior radiotherapy for breast cancer
Surgery:
- No prior definitive surgery for breast cancer
Other:
- No other concurrent anticancer therapy
Trial locations and contacts
314 sites in 1 country.
300 sites in 1 country
United States300 sites
Kapiolani Medical Center at Pali Momi
‘Aiea, Hawaii, 96701
Oncology Services of Aberdeen
Aberdeen, South Dakota, 57401
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
University of New Mexico Cancer Research and Treatment Center
Albuquerque, New Mexico, 87106
Lovelace Medical Center
Albuquerque, New Mexico, 87108
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
Harrington Cancer Center
Amarillo, Texas, 79106
American Fork Hospital
American Fork, Utah, 84003
Alaska Regional Hospital Cancer Center
Anchorage, Alaska, 99508
Rose Ramer Cancer Clinic at Anderson Area Medical Center
Anderson, South Carolina, 29621
Hope A Women's Cancer Center
Asheville, North Carolina, 28801
Mission Hospitals - Memorial Campus
Asheville, North Carolina, 28801
Auburn Regional Center for Cancer Care
Auburn, Washington, 98002
Rush-Copley Cancer Care Center
Aurora, Illinois, 60507
Seton Shivers Cancer Program at Brackenridge Hospital
Austin, Texas, 78701
CancerCare of Maine at Eastern Maine Medial Center
Bangor, Maine, 04401
Baton Rouge General Regional Cancer Center
Baton Rouge, Louisiana, 70806
Mary Bird Perkins Cancer Center - Baton Rouge
Baton Rouge, Louisiana, 70809
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
St. Francis Hospital and Health Centers
Beech Grove, Indiana, 46107
St. Joseph Hospital Community Cancer Center
Bellingham, Washington, 98225
Hematology Oncology Associates of the Quad Cities
Bettendorf, Iowa, 52722
Mecosta County General Hospital
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Deaconess Billings Clinic - Downtown
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare
Billings, Montana, 59101
Deaconess Billings Clinic Cancer Center
Billings, Montana, 59107
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Cancer Care Center at Medcenter One Hospital
Bismarck, North Dakota, 58501
Mid Dakota Clinic, P. C.
Bismarck, North Dakota, 58501
St. Alexius Medical Center
Bismarck, North Dakota, 58501
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
Boise, Idaho, 83706
St. Luke's Mountain States Tumor Institute - Boise
Boise, Idaho, 83712
Tufts - New England Medical Center
Boston, Massachusetts, 02111
Cancer Research Center at Boston Medical Center
Boston, Massachusetts, 02118
Wood County Oncology Center
Bowling Green, Ohio, 43402
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Internal Medicine Associates of Bozeman
Bozeman, Montana, 59715
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Roswell Park Cancer Institute
Buffalo, New York, 14263
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Community Hospital
Butte, Montana, 59701
St. Francis Medical Center
Cape Girardeau, Missouri, 63701
Saint Anthony Regional Hospital
Carroll, Iowa, 51401
St. Luke's Hospital
Cedar Rapids, Iowa, 52402
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Providence Centralia Hospital Regional Cancer Center
Centralia, Washington, 98531
Cancer Center of Kansas, P.A. - Chanute
Chanute, Kansas, 66720
Roper St. Francis Cancer Center at Roper Hospital
Charleston, South Carolina, 29401
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267
North Idaho Cancer Center
Coeur d'Alene, Idaho, 83814
Memorial Hospital Cancer Center
Colorado Springs, Colorado, 80909
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Alegent Health Mercy Hospital
Council Bluffs, Iowa, 51503
Medical City Dallas Hospital
Dallas, Texas, 75230
Danville Regional Medical Center
Danville, Virginia, 24541
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Genesis Medical Center - West Campus
Davenport, Iowa, 52804
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Dayton
Dayton, Ohio, 45429
Halifax Medical Center
Daytona Beach, Florida, 32115
Mercy Capitol Hospital
Des Moines, Iowa, 50307
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48202
Cancer Center of Kansas, P.A. - Dodge City
Dodge City, Kansas, 67801
Cancer Care Center at St. Luke's Hospital
Duluth, Minnesota, 55805
CCOP - Duluth
Duluth, Minnesota, 55805
Miller-Dwan Medical Center
Duluth, Minnesota, 55805
St. Mary's - Duluth Clinic Cancer Center
Duluth, Minnesota, 55805
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, P.A. - El Dorado
El Dorado, Kansas, 67042
Englewood Hospital and Medical Center
Englewood, New Jersey, 07631
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
St. Francis Hospital
Federal Way, Washington, 98003
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas, 72903
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, 46815
Fremont Area Medical Center
Fremont, Nebraska, 68025
Fremont Memorial Hospital
Fremont, Ohio, 43420
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Medical and Surgical Specialists, L L C
Galesburg, Illinois, 61401
Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
Gape Girardeau, Missouri, 63701
Glendale Memorial Hospital Comprehensive Cancer Center
Glendale, California, 91204
Legacy Mount Hood Medical Center
Glesham, Oregon, 97030
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Center for Cancer Care at Goshen Health System
Goshen, Indiana, 46527
Altru Cancer Center at Altru Hospital
Grand Forks, North Dakota, 58201
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Mercy Medical Center
Grand Rapids, Michigan, 49503
Spectrum Health Cancer Care - Butterworth Campus
Grand Rapids, Michigan, 49503
Metropolitan Hospital
Grand Rapids, Michigan, 49506
Spectrum Health Hospital - Blodgett Campus
Grand Rapids, Michigan, 49506
Great Falls Clinic
Great Falls, Montana, 59405
Sletten Regional Cancer Institute
Great Falls, Montana, 59405
Leo W. Jenkins Cancer Center at Pitt County Memorial Hospital
Greenville, North Carolina, 27858
Cancer Care Center at Catskill Regional Medical Center
Harris, New York, 12742
Saint Rose Hospital
Hayward, California, 94545
St. Peter's Hospital
Helena, Montana, 59601
Holland Community Hospital
Holland, Michigan, 49423
Memorial Cancer Institute at Memorial Regional Hospital
Hollywood, Florida, 33021
Cancer Research Center of Hawaii
Honolula, Hawaii, 96813
OnCare Hawaii, Incorporated - Lusitana
Honolulu, Hawaii, 96813
Queen's Cancer Institute at Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital, Incorporated
Honolulu, Hawaii, 96813
OnCare Hawaii, Incorporated - Kuakini
Honolulu, Hawaii, 96817
St. Francis Medical Center
Honolulu, Hawaii, 96817
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Tripler Army Medical Center
Honolulu, Hawaii, 96859
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Mayo Clinic - Jacksonville
Jacksonville, Florida, 32224-9980
Joliet Oncology Hematology Associates, Limited - West
Joliet, Illinois, 60435
Ella Milbank Foshay Cancer Center at Jupiter Medical Center
Jupiter, Florida, 33458
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Borgess Medical Center
Kalamazooaa, Michigan, 49001
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
Kansas City, Kansas, 66160
CCOP - Kansas City
Kansas City, Missouri, 64131
Good Samaritan Health Systems
Kearney, Nebraska, 68847
Kenton Oncology, Incorporated
Kenton, Ohio, 43326
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Cancer Center of Kansas, P.A. - Kingman
Kingman, Kansas, 67068
Lenoir Memorial Cancer Center
Kinston, North Carolina, 28501
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Wilford Hall Medical Center
Lackland Air Force Base, Texas, 78236
Haematology-Oncology Associates of Ohio and Michigan, P.C.
Lambertville, Michigan, 48144
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Markey Cancer Center at University of Kentucky Chandler Medical Center
Lexington, Kentucky, 40536
Southwest Medical Center
Liberal, Kansas, 67901
St. Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
Meeker County Memorial Hospital
Litchfield, Minnesota, 55355
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Valley Memorial Hospital
Livermore, California, 94550
Logan Regional Hospital
Logan, Utah, 84321
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804
UMC Southwest Cancer and Research Center
Lubbock, Texas, 79415
MedCentral - Mansfield Hospital
Mansfield, Ohio, 44903
St. John's Hospital
Maplewood, Minnesota, 55109
Northwest Ohio Oncology Center
Maumee, Ohio, 43537
St. Luke's Hospital
Maumee, Ohio, 43537
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Middletown Regional Hospital
Middletown, Ohio, 45044
Eastern Montana Cancer Center
Miles City, Montana, 59301
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Virginia Piper Cancer Institute at Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Community Medical Center
Missoula, Montana, 59801
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59802
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59802
Alegent Health Community Memorial Hospital
Missouri Valley, Iowa, 51555
Mobile Infirmary Medical Center
Mobile, Alabama, 36607
Trinity Medical Center - East
Moline, Illinois, 61265
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Mercy Memorial Hospital System
Monroe, Michigan, 48162
Ted B. Wahby Cancer Center at Mount Clemens General Hospital
Mount Clemens, Michigan, 48043
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Skagit Valley Hospital Cancer Care Center
Mount Vernon, Washington, 98273
Cottonwood Hospital Medical Center
Murray, Utah, 84107
Hackley Hospital
Muskegon, Michigan, 49443
Hematology Oncology Consultants Ltd.
Naperville, Illinois, 60540
Edward Hospital Cancer Center
Naperville, Illinois, 60566
MBCCOP - Meharry Medical College - Nashville
Nashville, Tennessee, 37208-3599
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
Medical Center of Louisiana - New Orleans
New Orleans, Louisiana, 70112
St. Vincent's Comprehensive Cancer Center - Manhattan
New York, New York, 10011
Cancer Center of Kansas, P.A. - Newton
Newton, Kansas, 67114
Highland General Hospital at St. George's University School of Medicine
Oakland, California, 94602
CCOP - Bay Area Tumor Institute
Oakland, California, 94609
Summit Medical Center
Oakland, California, 94609
McKay-Dee Hospital Center
Ogden, Utah, 84403
Providence St. Peter Hospital Regional Cancer Center
Olympia, Washington, 95806
Capital Medical Center
Olympia, Washington, 98507
Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields
Olympia Fields, Illinois, 60461
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Immanuel Medical Center
Omaha, Nebraska, 68122
Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Creighton University Medical Center
Omaha, Nebraska, 68131
Burgess Health Center
Onawa, Iowa, 51040
St. Charles Mercy Hospital
Oregon, Ohio, 43616
Toledo Clinic - Oregon
Oregon, Ohio, 43616
Comprehensive Cancer Center at Desert Regional Medical Center
Palm Springs, California, 92262
Midlands Cancer Center at Midlands Community Hospital
Papillion, Nebraska, 68046
Cancer Center of Kansas, P.A. - Parsons
Parsons, Kansas, 67357
Northern Michigan Hospital
Petoskey, Michigan, 49770
Olympic Medical Center
Port Angeles, Washington, 98362
Legacy Good Samaritan Hospital & Medical Center Comprehensive Cancer Center
Portland, Oregon, 97210
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Institute of Oncology at Vilnius University
Portland, Oregon, 97227
Cancer Institute at Oregon Health and Science University
Portland, Oregon, 97239
Cancer Center of Kansas, P.A. - Pratt
Pratt, Kansas, 67124
Utah Valley Regional Medical Center - Provo
Provo, Utah, 84603
Good Samaritan Cancer Center
Puyallup, Washington, 98372
Commonwealth Hematology-Oncology P. C. - Quincy
Quincy, Massachusetts, 02169
All Saints Cancer Center at All Saints Healthcare
Racine, Wisconsin, 53405
Rapid City Regional Hospital
Rapid City, South Dakota, 57701
Valley Medical Center
Renton, Washington, 98055
Hubert H. Humphrey Cancer Center at North Memorial Medical Center
Robbinsdale, Minnesota, 55422
Highland Hospital of Rochester
Rochester, New York, 14620
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642
Swedish American Hospital
Rockford, Illinois, 61104
William Beaumont Hospital - Royal Oak Campus
Royal Oak, Michigan, 48073
Rutherford Hospital
Rutherfordton, North Carolina, 28139
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Park Nicollet Health Services
Saint Louis Park, Minnesota, 55416
Regions Hospital Cancer Care Center
Saint Paul, Minnesota, 55101
St. Joseph's Hospital
Saint Paul, Minnesota, 55102
United Hospital
Saint Paul, Minnesota, 55102
Salem Hospital Regional Cancer Center
Salem, Oregon, 97309
Cancer Center of Kansas, P.A. - Salina
Salina, Kansas, 67042
Salina Regional Health Center
Salina, Kansas, 67401
Utah Cancer Specialists at UCS Cancer Center
Salt Lake City, Utah, 84106
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112
LDS Hospital
Salt Lake City, Utah, 84143
Veterans Affairs Medical Center - San Antonio (Murphy)
San Antonio, Texas, 78209
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229-3900
Cancer Therapy and Research Center
San Antonio, Texas, 78229
University Hospital - San Antonio
San Antonio, Texas, 78229
J.C. Robinson, M.D. Regional Cancer Center
San Pablo, California, 94806
Firelands Regional Medical Center
Sandusky, Ohio, 44870
North Coast Cancer Care, Incorporated
Sandusky, Ohio, 44870
New Mexico Cancer Care Associates
Santa Fe, New Mexico, 87505
Mayo Clinic Scottsdale
Scottsdale, Arizona, 85259
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98104
Group Health Central Hospital
Seattle, Washington, 98104
Harborview Medical Center
Seattle, Washington, 98104
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
Seattle, Washington, 98114
University Cancer Center at University of Washington Medical Center
Seattle, Washington, 98195
North Puget Oncology at United General Hospital
Sedro-Woolley, Washington, 98284
Saint Francis Cancer Center
Shakopee, Minnesota, 55379
Welch Cancer Center
Sheridan, Wyoming, 82801
Cancer Treatment Center at Christus Schumpert St. Mary Place
Shreveport, Louisiana, 71101
Siouxland Regional Cancer Center
Sioux City, Iowa, 51101-1733
Siouxland Hematology-Oncology Associates at June E. Nylen Cancer Center
Sioux City, Iowa, 51101
Mercy Medical Center - Sioux City
Sioux City, Iowa, 51104
St. Luke's Regional Medical Center
Sioux City, Iowa, 51104
Providence Cancer Institute at Providence Hospital - Southfield Campus
Southfield, Michigan, 48075
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
Spartanburg, South Carolina, 29303
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29304
Cancer Care Northwest - Spokane South
Spokane, Washington, 99202
Highlands Oncology Group - Springdale
Springdale, Arkansas, 72764
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65802
St. John's Regional Health Center
Springfield, Missouri, 65804
Hulston Cancer Center at Cox Medical Center South
Springfield, Missouri, 65807
Missouri Baptist Cancer Center
St Louis, Missouri, 63131
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141
David C. Pratt Cancer Center at St. John's Mercy
St Louis, Missouri, 63141
Dixie Regional Medical Center
St. George, Utah, 84770
Promedica Cancer Center at Flower Hospital
Sylvania, Ohio, 43560
Allenmore Hospital
Tacoma, Washington, 98405
CCOP - Northwest
Tacoma, Washington, 98405
St. Joseph Medical Center at Franciscan Health System
Tacoma, Washington, 98405
Madigan Army Medical Center
Tacoma, Washington, 98431
St. Clare Hospital
Tacoma, Washington, 98499
CCOP - Scott and White Hospital
Temple, Texas, 76508
Mercy Hospital of Tiffin
Tiffin, Ohio, 44883
Toledo Hospital
Toledo, Ohio, 43606
St. Vincent Mercy Medical Center
Toledo, Ohio, 43608
Medical College of Ohio Cancer Institute
Toledo, Ohio, 43614
CCOP - Toledo Community Hospital
Toledo, Ohio, 43623
Toledo Clinic, Incorporated - Main Clinic
Toledo, Ohio, 43623
Toledo Surgical Specialists
Toledo, Ohio, 43623
Stormont-Vail Cancer Center
Topeka, Kansas, 66604
St. Francis Comprehensive Cancer Center
Topeka, Kansas, 66606
Munson Medical Center
Traverse City, Michigan, 49684
UVMC Cancer Care Center at Upper Valley Medical Center
Troy, Ohio, 45373
Legacy Meridian Park Hospital
Tualatin, Oregon, 97062
Natalie Warren Bryant Cancer Center at St. Francis Hospital
Tulsa, Oklahoma, 74136
Carle Cancer Center at Carle Foundation Hospital
Urbana, Illinois, 61801
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
Southwest Washington Medical Center Cancer Center
Vancouver, Washington, 98668
Ridgeview Medical Center
Waconia, Minnesota, 55387
Fulton County Health Center
Wauseon, Ohio, 43567
Cancer Center of Kansas, P.A. - Wellington
Wellington, Kansas, 67152
Central Washington Hospital
Wenatchee, Washington, 98801
Wenatchee Valley Clinic
Wenatchee, Washington, 98801
About this study
Official title: A Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel As Neoadjuvant Therapy For Inflammatory and Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combination chemotherapy is more effective with or without filgrastim in treating breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of combining doxorubicin, cyclophosphamide, and paclitaxel with or without filgrastim in treating women who have inflammatory or locally advanced breast cancer.
Read the detailed description
OBJECTIVES:
- Compare the microscopic pathologic response rates in women with inflammatory or locally advanced breast cancer treated with standard neoadjuvant doxorubicin and cyclophosphamide followed by weekly paclitaxel vs weekly doxorubicin and daily oral cyclophosphamide with filgrastim (G-CSF) followed by weekly paclitaxel.
- Compare the toxic effects of these regimens in this patient population.
- Compare the delivered dose intensity of these regimens in this patient population.
- Evaluate the association between microscopic pathologic complete response and clinical complete response at the primary tumor site in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to disease status (inflammatory vs other). Patients are randomized to one of two treatment arms.
- Arm I: Patients receive doxorubicin IV followed by cyclophosphamide IV on day 1. Treatment repeats every 21 days for a total of 5 courses in the absence of disease progression or unacceptable toxicity. Three weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour weekly on day 1 for a total of 12 weeks.
- Arm II: Patients receive doxorubicin IV on day 1, oral cyclophosphamide on days 1-7, and filgrastim (G-CSF) subcutaneously on days 2-7. Treatment repeats weekly for a total of 15 courses of doxorubicin and cyclophosphamide and 16 courses of G-CSF in the absence of disease progression or unacceptable toxicity. One week after completion of G-CSF, patients receive paclitaxel as in arm I.
Within 3-6 weeks after completion of chemotherapy, patients with stable or responsive disease undergo surgical resection of tumor and affected nodes.
After surgery, patients may receive radiotherapy or additional chemotherapy and/or hormonal therapy at the discretion of the treating physician.
Patients are followed every 6 months for 1 year and then annually for 4 years.
PROJECTED ACCRUAL: A total of 350 patients (175 per treatment arm) will be accrued for this study within 3 years.
- Conditions
- Breast Cancer
- Being tested
- filgrastim, cyclophosphamide, doxorubicin, paclitaxel, surgery
- Keywords
- stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, inflammatory breast cancer
- Medical subject headings
- Breast Neoplasms, Inflammatory Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
filgrastimBiological
Also called G-CSF
cyclophosphamideDrug
Also called cytoxan
doxorubicinDrug
Also called Adriamycin
paclitaxelDrug
surgeryProcedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| AC followed by P | Active comparator | doxorubicin and cyclophosphamide followed by paclitaxel followed by surgery Receives: Drug: cyclophosphamide; Drug: doxorubicin; Drug: paclitaxel; Procedure: surgery |
| AC+G followed by P | Experimental | weekly doxorubicin and daily cyclophosphamide with filgrastim followed by paclitaxel followed by surgery Receives: Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin; Drug: paclitaxel; Procedure: surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison of microscopic pathologic response rates
Measured: no sooner than 21 days after chemo
Toxicity
Measured: during chemo and at surgery
Comparison of delivered dose intensity
Measured: after chemo
Correlation of microscopic pathologic complete response with clinical complete response at the primary tumor site
Measured: no sooner than 21 days after chemo
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study startMay 2001
- Primary completionSep 2006
- Study completionFeb 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 399 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Georgiana K. Ellis, MD, Study chair, Seattle Cancer Care Alliance
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00016406
- Sponsor's protocol ID
- CDR0000068630
- Other IDs
- S0012, U10CA032102
- Status last verified
- Jan 2013
- First submitted
- 6 May 2001
- Last updated
- 24 Jan 2013
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Slovak ML, Bedell V, Lew D, et al.: Screening for clonal hematopoiesis as a predictive marker for development of t-AML following adjuvant therapy for breast cancer (S0012). [Abstract] J Clin Oncol 25 (Suppl 18): A-11051, 2007.
Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol. 2011 Mar 10;29(8):1014-21. doi: 10.1200/JCO.2009.27.6543. Epub 2011 Jan 10.
PubMed 21220618Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston RB, Martino S, Perez EA, Hortobagyi GN, Sher D, Stock W. Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Res Treat. 2010 Jan;119(2):391-8. doi: 10.1007/s10549-009-0597-5.
PubMed 19851858
Study at a glance
From the registry record, last updated by the sponsor on 24 Jan 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel As Neoadjuvant Therapy For Inflammatory and Locally Advanced Breast Cancer
- ClinicalTrials.gov ID
- NCT00016406
- Acronym / sponsor ID
- CDR0000068630
- Conditions
- Breast Cancer
- Keywords
- stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, inflammatory breast cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 399 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- May 2001
- Primary completion
- Sep 2006 (actual)
- Study completion
- Feb 2012 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combination chemotherapy is more effective with or without filgrastim in treating breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of combining doxorubicin, cyclophosphamide, and paclitaxel with or without filgrastim in treating women who have inflammatory or locally advanced breast cancer.
Detailed description
OBJECTIVES:
- Compare the microscopic pathologic response rates in women with inflammatory or locally advanced breast cancer treated with standard neoadjuvant doxorubicin and cyclophosphamide followed by weekly paclitaxel vs weekly doxorubicin and daily oral cyclophosphamide with filgrastim (G-CSF) followed by weekly paclitaxel.
- Compare the toxic effects of these regimens in this patient population.
- Compare the delivered dose intensity of these regimens in this patient population.
- Evaluate the association between microscopic pathologic complete response and clinical complete response at the primary tumor site in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to disease status (inflammatory vs other). Patients are randomized to one of two treatment arms.
- Arm I: Patients receive doxorubicin IV followed by cyclophosphamide IV on day 1. Treatment repeats every 21 days for a total of 5 courses in the absence of disease progression or unacceptable toxicity. Three weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour weekly on day 1 for a total of 12 weeks.
- Arm II: Patients receive doxorubicin IV on day 1, oral cyclophosphamide on days 1-7, and filgrastim (G-CSF) subcutaneously on days 2-7. Treatment repeats weekly for a total of 15 courses of doxorubicin and cyclophosphamide and 16 courses of G-CSF in the absence of disease progression or unacceptable toxicity. One week after completion of G-CSF, patients receive paclitaxel as in arm I.
Within 3-6 weeks after completion of chemotherapy, patients with stable or responsive disease undergo surgical resection of tumor and affected nodes.
After surgery, patients may receive radiotherapy or additional chemotherapy and/or hormonal therapy at the discretion of the treating physician.
Patients are followed every 6 months for 1 year and then annually for 4 years.
PROJECTED ACCRUAL: A total of 350 patients (175 per treatment arm) will be accrued for this study within 3 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| AC followed by P | Active comparator | Drug: cyclophosphamide, Drug: doxorubicin, Drug: paclitaxel, Procedure: surgerydoxorubicin and cyclophosphamide followed by paclitaxel followed by surgery |
| AC+G followed by P | Experimental | Biological: filgrastim, Drug: cyclophosphamide, Drug: doxorubicin, Drug: paclitaxel, Procedure: surgeryweekly doxorubicin and daily cyclophosphamide with filgrastim followed by paclitaxel followed by surgery |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| filgrastimAlso: G-CSF | Biological | AC+G followed by P |
| cyclophosphamideAlso: cytoxan | Drug | AC followed by P, AC+G followed by P |
| doxorubicinAlso: Adriamycin | Drug | AC followed by P, AC+G followed by P |
| paclitaxel | Drug | AC followed by P, AC+G followed by P |
| surgery | Procedure or surgery | AC followed by P, AC+G followed by P |
Primary outcome
Comparison of microscopic pathologic response rates
Time frame: no sooner than 21 days after chemo
Toxicity
Time frame: during chemo and at surgery
Comparison of delivered dose intensity
Time frame: after chemo
Correlation of microscopic pathologic complete response with clinical complete response at the primary tumor site
Time frame: no sooner than 21 days after chemo
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jan 2013.
- Results publicationSlovak ML, Bedell V, Lew D, et al.: Screening for clonal hematopoiesis as a predictive marker for development of t-AML following adjuvant therapy for breast cancer (S0012). [Abstract] J Clin Oncol 25 (Suppl 18): A-11051, 2007.
- Results publication: PubMed 21220618Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol. 2011 Mar 10;29(8):1014-21. doi: 10.1200/JCO.2009.27.6543. Epub 2011 Jan 10.
- Derived from this study: PubMed 19851858Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston RB, Martino S, Perez EA, Hortobagyi GN, Sher D, Stock W. Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Res Treat. 2010 Jan;119(2):391-8. doi: 10.1007/s10549-009-0597-5.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Georgiana K. Ellis, MD study chair
Seattle Cancer Care Alliance
314 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing filgrastim, cyclophosphamide and doxorubicin in people with Breast Cancer, run by SWOG Cancer Research Network at 314 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 314 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison of microscopic pathologic response rates (time frame: no sooner than 21 days after chemo). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00016406, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jan 2013.